Asia's first and only proprietary tech-based NGS target capture kit developer Celemics develops target capture kits for next-generation sequencing (NGS) applications based on its proprietary molecular cloning technology called MSSIC (Massively Separated and Sequence-Identified Cloning). Target capture kits, which play a key role in NGS technology-based targeted sequencing, are commercially produced by only six companies in the world including Celemics. Investment points: 1) rapid NGS market growth; 2) business/overseas expansion The global NGS market continues to grow alongside technological advancements and sequencing cost declines. In addition to diagnostics, NGS technology is expected to be used in a wider range of applications including new drug development, microbiome, and seed development. As a result, the size of the global NGS market is projected to grow at a rapid pace from USD6.3bn in 2018 to USD31.4bn (KRW35tr) by 2026. Steep market growth, in turn, should lead to stronger demand for target capture kits. Celemics, backed by its advanced technology and services vs. peers, will likely enjoy notable growth in market share going forward. In addition, the company’s expansion into sequencing solutions and overseas markets should pick up pacefrom 2020 with the release of its NGS solution, BTSeq (Barcode-Tagged Sequencing). Initiate coverage with BUY and a conservative target price of KRW40,000 We initiate coverage of Celemics with BUY for a target price of KRW40,000. Our target price is based on the present value of the EPS forecast of KRW1,239 for 2022 (reflecting expectations for improvement in operating margins to peer average levels backed by overseas and BTSeq sales) and a target PER of 37.9x (15% discount to the PER average of peers). On the first day of listing, Celemics shares gained just 29% vs. the IPO price. However, we believe Celemics sets itself apart from other listed domestic NGS companies, as: 1) one of the six companies in the world that have succeeded in the commercialization of target capture kits for NGS applications; and 2) a company capable of expanding beyond the domestic market to overseas markets for faster earnings growth. Recently-listed US peer Twist Bioscience is currently trading at a market cap of USD3bn (roughly KRW3.6tr), even with the company's target capture kit-related sales standing at just KRW25.3bn as of 2019. Considering the upbeat earnings outlook, Celemics shares appear excessively undervalued at current price levels.
NGS Target Enrichment Panel
Celemics pushes the limits of current NGS solutions in performance, flexibility, and cost.
Our hybridization-based target enrichment panel shows superior capture performance
especially in GC-rich, pseudogene and various homologous regions.
Meet our panels for inherited disease, oncology, liquid biopsy, AgBio and pharma applications.
SARS-CoV-2 Whole Genome Sequencing Service
Celemics provides complete SARS-CoV-2 whole-genome sequences within 2-3 days,
even for contaminated specimens or samples of minuscule quantities.
Our unique enrichment assay and bioinformatics algorithm enable accurate full sequence
analysis with low coverage bias.
Contiguous Sequencing Service
Celemics provides an innovative NGS-based sequencing solution that overcomes
the limitations of Sanger sequencing’s primer walking step, enabling significantly faster,
accurate, and cost-effective analysis for sequences up to 20kb.
- Celemics Story
- Celemics innovates NGS-Based material with novel sequencing technology to disrupt the paradigm of medicine, biopharmaceutics, microbiome, agricultural biotechnology, and synthetic biology industries. We aid our customers on the front line to combat diseases and push the boundaries of biotechnology.
News and Events
Celemics bags $800K deal to supply gene expression profilers to Firalis SA
Celemics has signed a $800,000 contract to supply its Next-Generation Sequencing (NGS)-based gene expression profilers for neurodegenerative disease to Firalis S.A., a France-based developer and provider of biomarker diagnostic products. Shares of Kosdaq-listed Celemics traded a tad higher in the morning session on Wednesday. According to its disclosure on Wednesday, Celemics will provide Firalis with NeuroMICS products for PAXgene/PBMC and Plasma/Saliva until 2022. The deal value represents about 18 percent of Celemics’ revenue last year.
Oct. 28. 2020
Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution
Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications.To serve as an end-to-end workflow with integrated genomic data analysis, Celemics partnered with BlueBee, an industrial-grade and highly configurable data platform provider, to develop a bioinformatics solution tailored for their assay and end-user experience. Collaborative efforts between these two industry leaders produced the Celemics web solution, offering a new level of accessibility to users of target enrichment NGS assays. The Celemics web solution will act as a springboard to propel research towards precision medicine and provide Celemics with an extensible, highly efficient and scalable data strategy poised for growth. The Celemics web solution is a turnkey analytics option, transforming raw data into actionable results as part of the Celemics NGS target enrichment kit portfolio. "Data analysis is a critical workflow area with potential for streamlining," says Dr. Hyoki Kim, CEO Celemics. "We chose BlueBee to address the data analysis bottleneck for our customers with a platform that fits precisely with our assay. The Celemics web solution standardizes the digital end of the workflow, is high-performance, and provides ease of use. This strategic product extension is directly in line with our company mission of accelerating precision medicine, which we are thrilled to make tangible for a global market," Dr. Kim adds. Leveraging BlueBee's Genomics Platform, Celemics is able to serve an expanding global market with clinical-grade data compliance and guaranteed data residency for customers in Europe, Asia, and beyond. The administrator features of the platform ensure that Celemics remains in complete control of their pipeline and operations. The streamlined user interface enables end-users with any level of expertise to analyze, interpret, and return actionable results from their sequencing workflow. Celemics end-users may also work collaboratively, providing secure, permissioned, and audited access of project data and analyses. "We are honored to serve Celemics," says Hans Cobben, CEO of BlueBee. "The BlueBee Genomics Platform, configured for the Celemics data workflow, will streamline data analysis through insight generation for target enrichment applications, and support market expansion for Celemics. Partnerships like this that bridge the gap between wet-lab and data workflows, are critical to the pursuit of precision medicine," Cobben adds. About Celemics Celemics is a biotech company developing and supplying key enabling solutions in the field of genomics, antibody discovery and synthetic biology. As a manufacturer of target enrichment kits for NGS applications, Celemics secured itself in the global market for genetic testing. Celemics offers defined panels and customized target enrichment kits in IVD and RUO sector with remarkable synthetic probe rebalancing technology under stringent quality management system (ISO 9001, ISO 13485, GMP). Founded 2010, Celemics has been focused in the last several years on providing target enrichment panels in Europe and Asia for various applications including oncology, inherited disease and genetic marker discovery.
Oct. 15. 2019
[WFMJ] Breakthrough test kit identifies 39 virus strains including Covid-19 mutations
News Link: https://www.wfmj.com/story/43133566/breakthrough-test-kit-identifies-39-virus-strains-including-covid-19-mutations
Jan. 06. 2021
Celemics Core Products & Service
NGS Target Enrichment Panel
- Customized Panel
- Pre-set Panels
- * BRCA1,2 / OncoRisk Panel / CES Panel / PharmacoScreen Panel * CancerScreen Panel / Pan-Cancer Panel * Comprehensive Respiratory Virus Panel
BTSeq™ SARS-CoV-2 Sequencing Service
- Viral whole genome sequencing
- Amplicon sequencing
- Gene panel sequencing (RdRp, S, E, M, N)
BTSeq™ Contiguous Sequencing Service
- VNGS-based full sequencing, 2-3 days for up to 20kb
- Plasmid, amplicon, colony sequencing
- How TrueRepertoire™ accelerates your research
- Sequence scFv or Fab libraries, analyze entire variable regions, and process over 10,000 clones in a single experiment with TrueRepertoire™, an NGS-based antibody sequencing platform aiming to overcome key research issues including frequent sequencing errors, short read length, and high costs for future gene synthesis.
Our Global Network
Expansion of global market share by entering new frontiers worldwide Promotion of our long-term vision by focusing our capabilities on pioneering the global market
- AmpliTech SAS 8, Avenue de Flandres Dunkerque 60200 COMPIEGNE FRANCE
- Intron Saglik
- İsmet Kaptan Mahallesi, Sezer Doğan Sokak, No: 20, Apartment: 1, PK 35210 KONAK / İZMİR | Turkey
- VH Bio Ltd
- 11B Station Approach, Gateshead NE11 0ZF, United Kingdom
- Singapore Office Tree Code Pte. Ltd (201308649C) 20 Science Park Road, #01-31 Teletech Park, Singapore 117674.
- Coming Century Company
- Al-Mirgab, Block # 1, Near Masjid Al-Shamlan (Round About Mosque), Star Tower, Floor 22, Office # 3, P.O.Box: 411, Dasman, 15455, Kuwait